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RRR-α-tocopherol derivative α-TEA (RRR-α-tocopherol ether-linked acetic acid analog) has been shown to be a potent antitumor
agent both in vivo and in vitro. In this study, we investigated the eﬀects of α-TEA on the expression of epidermal growth factor
receptor(EGFR)familymembers,ErbB1,2and3,andtheroleofErbB2and3inα-TEA-inducedapoptosisandsuppressionofAkt,
FLIP and survivin in the cisplatin-sensitive (A2780S) and -resistant (A2780/CP70R) human ovarian cancer cell lines. Data show
that α-TEA’s ability to induced apoptosis was associated with reduced expression of ErbB1 (cisplatin-resistant cells), 2 and 3 (both
cell types) and reduced levels of the phosphorylated (active) form of Akt; as well as, reduced levels of FLIP and survivin proteins
in both cell types. Ectopic overexpression and siRNA knockdown studies showed that ErbB2, ErbB3, Akt, FLIP and survivin are
involved in α-TEA-induce apoptosis and that α-TEA downregulates FLIP and survivin via suppression of pAkt, which is mediated
by ErbB2and ErB3. Thus,α-TEA is a potent pro-apoptotic agent for both cisplatin-sensitive and -resistantovarian cancer cell lines
in cell culture and it produces cell death, at least in part, by downregulation of members of the EGFR family.
1.Introduction
Ovarian cancer ranks eighth among all cancers in women
in terms of estimated new cases and ﬁfth in estimated
deaths [1]. A majority of patients with ovarian cancer
require treatment with cytotoxic chemotherapy. Platinum
agents, cisplatin or carboplatin, are the most eﬀective ﬁrst-
linetreatments;however, despite initial promising responses,
a high percentage of cases develop chemoresistance which
signiﬁcantly hinders successful treatment outcomes [2, 3].
Thus, there is a great need to develop agents for treatment
of drug resistant ovarian tumors.
The epidermal growth factor receptor (EGFR) family
(ErbB family) of type I receptor tyrosine kinases (RTKs)
has four members: EGFR/ErbB1, ErbB2, ErbB3, and ErbB4
(also referred to as HER1, HER2, HER3 and HER4). All
ErbB family members share common features including
an extracellular ligand-binding domain (except ErbB2),
a transmembrane domain, and an intracellular protein
tyrosine kinase domain (except ErbB3). The receptors have
notable diﬀerences in their sequences, which account for
diﬀerential ligand-binding and diverse aﬃnities for down-
stream signaling molecules [4, 5]. Data suggest that the
homo- and heterodimerization between members of the
ErbB family as well as the ability of their ligands to
bind and activate more than one receptor help produce
the complex signaling pathways of these membrane-bound
proteins [6]. ErbB receptors not only play key roles in
normal developmental processes but also are implicated
in malignant transformation [6]. Activated ErbB receptors
stimulate many intracellular signaling pathways, especially
the phosphatidylinositol 3-kinase (PI3K)-AKT pathway [7].2 Journal of Oncology
Akt/protein kinase B is a family of serine-threonine pro-
tein kinases that promote cell survival and proliferation [8,
9]. Abnormal activation of Akt signaling has been reported
in several human cancers [8, 10, 11] including approximately
30–40%ofovariancancers[9,12].Aktpromotescellsurvival
by mediating inactivating phosphorylation of proapoptotic
proteins like Bad and caspase-9 and mediating activating
phosphorylation of NF-kappaB, which controls expression
of prosurvival proteins such as survivin, Bcl-2, and the
caspase-8inhibitorFLIP[13,14].Additionally,activeAkthas
been shown to confer resistance to chemotherapy in human
cancers and is considered a therapeutic target [8, 11, 12].
Impairment of apoptotic processes can also be mediated
by factors such as FLIP and survivin. FLIP and survivin
are cytoplasmic proteins that function as inhibitors of
caspase-8 and caspase-9/3, respectively, [15, 16]. FLIP has a
similar structure to caspase-8 without the catalytic domain
and thus competitively inhibits caspase-8 binding to the
tumor necrosis factor family of cell surface death receptors
thus blocking their apoptotic signaling [15]. Survivin is
a structurally unique member in the IAP (inhibitor of
apoptosis protein) family [16] and suppresses the processing
and catalytic activity of execution caspases, such as casapse-9
and 3 [17].
Our lab has developed a vitamin E analog, 2,5,7,8-
tetramethyl-2R-(4R, 8R, 12-trimethyl-tridecyl chroman-6-
yloxy)aceticacid,referredtoasalpha-tocopheroletheracetic
acid analog (α-TEA), which diﬀers in structure and function
from natural vitamin E (RRR-α-tocopherol). α-TEA has an
acetic acid moiety linked to the phenolic oxygen at carbon 6
o ft h ec h r o m a nh e a do fR R R - α-tocopherol by an ether link-
age yielding a stable, nonhydrolyzable entity [18, 19]. Studies
havedemonstratedthatα-TEAcanreducetumorburdenand
inhibit lung metastases when delivered by aerosol or in the
diet inpreclinical syngeneic transplantablemouse mammary
cancer studies [18–21]; as well as in xenograft models
using immune compromised mice transplanted with human
ovarian, breast or prostate cancer cells [22–24]. Immuno-
histochemical analyses of tumor tissue from α-TEA treated
animals indicated that α-TEA reduction of tumor burden
wasassociatedwithincreasedapoptosisandreducedcellpro-
liferationintumortissue[18–20,22–24].Cellculturestudies
have shown that α-TEA induces human ovarian, prostate
and breast cancer cells to undergo DNA synthesis arrest
and apoptosis, and that α-TEA-induced apoptosis involves
activation of Fas/Fas Ligand and c-Jun NH2-terminal kinase
(JNK) proapoptotic pathways; as well as, suppression of Akt,
FLIP,andsurvivinantiapoptotic/prosurvivalfactors[24–27].
In this study, we investigated the eﬀect of α-TEA on the
expression of EGFR family proteins and studied the roles
of ErbB2 and ErbB3 in α-TEA-induced apoptosis and sup-
pression of Akt, FLIP and survivin antiapoptotic/prosurvival
factors.
2.MaterialsandMethods
2.1. Chemicals. α-TEA (F.W. = 488.8) was prepared in house
as described previously [18]. LY294002, a speciﬁc inhibitor
of the p110 catalytic subunit of PI3K [28], and Wortmannin
[29], a cell-permeable, irreversible inhibitor of PI3K, were
purchased from Calbiochem (San Diego, CA).
2.2. Cell Lines and Treatments. The human ovarian A2780
cisplatin-sensitive parental cancer cell line (designated
A2780S), provided by Dr. J. Rebecca Liu (University of
Michigan Medical School, Ann Arbor, MI), was origi-
nally established from an untreated ovarian cancer patient
[30].Thecisplatin-resistantA2780/CP70variant(designated
A2780/CP70R), provided by Dr. Michael J. Birrer (Depart-
ment of Cell and Cancer Biology, National Cancer Institute,
Rockville, MD), was created through intermittent exposure
of A2780 cells to increasing concentrations of cisplatin (up
to 70μM) in vitro [31]. A2780S and A2780/CP70R cells were
grownasmonolayersonplastic(CorningPlasticWare,Corn-
ing, NY) and maintained at 37
◦C in RPMI 1640 (Invitrogen-
Life Technologies, Inc., Carlsbad, CA), supplemented with
10% fetal bovine serum (FBS, Gemini Bio-Products, Wood-
land, CA), 100IU/mL penicillin, 100μg/mL streptomycin,
and 2mM glutamine (Sigma Chemical Co., St. Louis, MO).
Cultures were maintained and routinely examined to verify
the absence of Mycoplasma contamination as described
previously [32].
For experiments, the percentage of FBS was reduced to
2%. Exponentially growing A2780S and A2780/CP70R cells
were plated at a density of 3 × 106 in T75 ﬂasks (10mL)
for Western analyses, or at a density of 1.5 × 105/well in 12-
well plates (1mL) for apoptosis analyses. Cells were allowed
to attach overnight before treatment initiation. Treatments
were conducted at various concentrations of α-TEA in a
ﬁnal concentration of 0.1–0.25% ethanol. Equal volume of
ethanol was used as vehicle control.
2.3. Cell Proliferation Assay. To study the eﬀects of α-
TEA on proliferation, A2780S or A2780/CP70R cells were
trypsinized, and seeded in triplicate into 96-well plates at a
density of 5000cells/well which yields a 20–30% cell density.
α-TEA at 1.25, 2.5 or 5μM, or 2.5, 5, or 10μMw e r e
then added to A2780S or A2780/CP70R, respectively, and
cells were grown in media containing 2% FBS for 1 to 3
days. Viable cell numbers were determined using Promega’s
CellTiter 96 Aqueous One Solution Cell Proliferation MTS
assay (Promega, Madison, WI) according to the manufac-
turer’s instructions.
2.4.ApoptosisAssay. Assessmentofapoptosiswasperformed
based on nuclear morphology of DAPI-stained cells as
described previously [33]. Cells in which the nucleus
contained clearly condensed chromatin or cells exhibiting
fragmented nuclei were scored as apoptotic. Apoptotic data
are reported as percentage of apoptotic cells in a given
cell population sample. For each sample, a minimum of 3
counts involving a minimum of 100–200cells/count were
scored. Apoptotic data are presented as the mean ± SD for
three independently performed experiments. Reagents for
morphological analyses of apoptosis were purchased from
Boehringer Mannheim Corp. (Indianapolis, IN).Journal of Oncology 3
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Figure 1: Eﬀects of α-TEA on cell growth and apoptosis in A2780S and A2780/CP70R cells. (a) A2780S and A2780/CP70R cells were plated,
cultured and treated as described in Section 2. Assessment of viable cell numbers (absorbance) was determined by the MTS assay following
treatment with diﬀerent doses of α-TEA for 1, 2 and 3 days. (b) Following treatment of cells with various concentrations of α-TEA or vehicle
control for 1, 2, or 3 days, ﬂoating and adherent cells were harvested, washed, and stained with DAPI. Apoptosis was determined by counting
the number of cells exhibiting condensed and fragmented nuclear morphology, and reported as percent apoptosis. Data in (a) and (b) are
depicted as the mean ± SD for three independent experiments (∗ = P<. 05 in comparison to vehicle control).
2.5. Western Immunoblot Analyses. Antibodies used to detect
pro- and cleaved caspase 3 (sc-7148), pro- and cleaved
caspase9 (sc-8355), HA-probe (sc-805), survivin(sc-17799),
ErbB-2 (sc-284), ErbB-3 (sc-285), ErbB-4 (sc-283), and
PARP (Poly(ADP-Ribose) Polymerase) (sc-7150), were pur-
chased from Santa Cruz Biotechnology, (Santa Cruz, CA).
Antibodiesusedtodetectpro-andcleavedcaspase8(#9746),
phospho-AKT (Ser 473) (#9271), AKT (#9272), phospho-
GSK-3α/β (Ser 21/9) (#9331), GSK-3β (#9332), and ErbB1
(#2232) were purchased from Cell Signaling Technology
(Beverly, MA). Monoclonal antibody to human FLIP was
purchased from Alexis Biochemical (ALX-804-428-C050);
and GAPDH was made in-house. GAPDH was used for
monitoring lane loads as described previously [33]. Whole
cell lysates were prepared and 50μgp r o t e i nw a sl o a d e dp e r
lane. Proteins were separated by using 10–15% SDS-PAGE
under reducing conditions and were electroblotted onto a
nitrocellulose membrane. Immunoblotting was performed
using primary rabbit or mouse antibodies and peroxidase-
conjugated goat antirabbit or antimouse, respectively, as the
secondary antibodies (Jackson Immunoresearch Laboratory,
West Grove, PA) at a 1 : 2000 dilution, followed by detection
with ECL (Pierce, Rockford, IL). Quantiﬁcation of band
intensity was performed using Scion Image Software (Scion
Corporation, Frederick, MD).
2.6. RNA Interference. ErbB2 and ErbB3 siRNA duplexes
were synthesized by Qiagen (Valencia, CA, USA) [34]. The
targeted sequences (sense strand were as follows: ErbB3:
AAGAGCGACTAGACATCAAGC; ErbB2: AAGTACACG-
ATGCGGAGACTG. Nonsilencing control siRNA (sc-37007)
was from Santa Cruz Biotechnology, (Santa Cruz, CA): Cells4 Journal of Oncology
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Figure 2:Twoantiapoptoticmolecules,FLIPandsurvivin,aredownregulatedbyα-TEAinbothcelltypes,andoverexpressionofeitherFLIP
or survivin blocks α-TEA-induced apoptosis. (a) Cells were treated with α-TEA for various time periods and whole cell lysates were analyzed
by western immunoblotting. ((b) and (c)) Cells were transiently transfected with empty vector control (pcDNA3), survivin (myc-survivin)-
or FLIP (his-FLIP-L)-expression plasmids. After 24 hours of transfection, cells were treated with or without α-TEA (20 or 40μM for A2780S
and A2780/CP70R, resp.) for 1 day prior to DAPI analysis for apoptosis (b), and for 12 hours prior to immunoblot analysis (c). Data in (a)
and (c) are representative of a minimum of two independent experiments. Data in (b) are depicted as the mean ± SD for three independent
experiments (∗ = P<. 001 in comparison to vector control).
were permitted to attach overnight and then were transiently
transfected with ErbB2, ErbB3 or non-silencing control
siRNAs at a ﬁnal concentration of 30nM in Lipofectamine
2000 Reagent from Invitrogen Corporation (Carlsbad, CA)
following manufacturer’s instructions. After one day trans-
fection, the cells were recultured in 100mm dish at 2 × 106
cells/dish for western blot and 1.5 × 105/12 well plate for
apoptosis.
2.7. Ectopic Expression of ErbB-2 and ErbB-3. The hemag-
glutinin epitope-tagged constitutively active (Myr)-AKT2
construct, HA-Myr-AKT2, and wildtype survivin expressionJournal of Oncology 5
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Figure 3: α-TEA decreased levels of the phosphorylated (active) form of Akt and its downstream substrate p-GSK3β. Overexpression of
constitutively active Akt blocks α-TEA’s ability to downregulate FLIP and survivin, while combinations of α-TEA and chemical inhibitors
of PI3K are better at inducing apoptosis and downregulating FLIP and survivin than single treatments. (a) Cells were treated with 20μM
(A2780S) or 40μM (A2780/CP70R) of α-TEA for 3, 6, 12, and 24 hours or vehicle control for 24 hours. Cell lysates from each treatment were
analyzed by immunoblotting for pAkt, total Akt, pGSK3β (Ser-9), and GSK3β. Numbers cited under lanes represent densitometric analyses
ofα-TEAtreatedsamplescomparedtovehiclecontroltreatedsamplesnormalizedforanylaneloaddiﬀerences.(b)Immunoblottinganalyses
were conducted on whole cell lysates from A2780S and A2780/CP70R cells transiently transfected with HA-Myr-AKT2 plasmid, following
treatment with α-TEA at 20 or 40μM, respectively, for 12 hours. (c) Cells were treated with two PI3K inhibitors, LY294002 (10μM) or
wortmannin (1μM), and cultured with or without α-TEA (10 or 20μM for A2780S and A2780/CP70R cells, resp.) for 15 hours. At the end
of the treatment period, cells were collected and total proteins were extracted for Western blot. All data are representative of a minimum of
two independent experiments.6 Journal of Oncology
plasmids were kindly provided by Dr. Jin Q. Cheng
(Department of Pathology, Molecular Oncology, and Drug
Discovery Programs, University of South Florida College
of Medicine, H. Lee Moﬃtt Cancer Center and Research
Institute, Tampa, FL) [35]. The constitutively active AKT
is tagged at the carboxy-terminus with a hemagglutinin
epitope tag and is modiﬁed at its aminoterminus with
the c-Src-derived myristylation signal (MGSSKSKPK) [36].
The wildtype survivin expression plasmid was created by
subcloning a PCR product of survivin into Myc-tagged
pcDNA3.1 and conﬁrmed by DNA sequencing analysis
[37]. The wildtype His-tagged FLIP expression construct,
pcDNA3.1-His-cFLIP-L, was kindly provided by Dr. John C.
Reed (The Burnham Inst. La Jolla, CA) [38]. The pEGFP-C1
vector (Clontech, Mountain View, CA) was used to express
enhanced green ﬂuorescent protein (EGFP) in cells as a
measure of transfection eﬃciency. The pcDNA3.1 expression
construct containing ErbB3 was provided by Dr. Xiaofeng
Li (MD Anderson Cancer Center) [39], and the expression
construct of ErbB2 was kindly provided by Dr. Atanasio
Pandiella(InstitutodeMicrobiologiaBioquimicaandCentro
de Investigacion del Cancer, CSIC, Universidad de Sala-
manca, Salamanca, Spain) [40]. A2780S and A2780/CP70R
cells were plated at 1.5 × 106 cells/100mm2 cell culture
dishes for Western immunoblot analyses and at 1.5 ×
105 cells/well in 12-well plates for apoptosis analyses. Cells
were permitted to attach overnight and then were transiently
transfected with mammalian expression vectors or appro-
priate vector control. Brieﬂy, cells were washed two times
with serum-free media (RPMI) and were incubated with
0.5mL of serum-free media (OPTI-MEM I, Gibco, Grand
Island, NY) containing 100μL of DNA/LipofectAMINE/Plus
(Invitrogen, Carlsbad, CA) complex for apoptosis studies,
and 4mL of serum free medium (MEM-Option) containing
800μL of DNA/LipofectAMINE/Plus complex for West-
ern immunoblot studies. DNA/LipofectAMINE/Plus reagent
complex was made by ﬁrst mixing 0.7μgo fD N A / 5 0μLo f
serum-freemediumwith5μLofPlusreagentfollowedby15-
minute incubation, and then mixing the DNA/Plus reagent
with 2μL of LipofectAMINE reagent/50μL of serum-free
media followed by 14-minute incubation. After overnight
transfection, cells were treated with α- T E Af o r2d a y sb e f o r e
analyses for apoptosis or for 12 hours before Western
immunoblot analyses.
2.8. Statistical Analysis. All experiments were performed two
or more times and experimental results were analyzed for
statisticalsigniﬁcanceusing2-tailt test.Thesigniﬁcancelevel
was set at P<. 05.
3. Results
3.1. α-TEA Inhibits Cell Growth and Induces Apoptosis in
a Dose- and Time-Dependent Manner. Cells in monolayer
cultures were treated with α-TEA (0, 1.25, 2.5, or 5μMf o r
A2780S or 0, 2.5, 5, or 10μM for A2780/CP70R cells) for 1,
2, or 3 days, and viable cell numbers were determined by
MTS assay. As illustrated in Figure 1(a), α-TEA decreased
viable A2780S and A2780/CP70R cell numbers in a dose-
and time-dependent manner. To conﬁrm that the reduction
in cell viability following α-TEA treatment was due to the
induction of apoptosis, cells were treated with diﬀerent
levels of α-TEA for 1, 2, and 3 days, and apoptosis was
measured by morphological analyses of cells stained with
the DNA dye DAPI (Figure 1(b)). A2780S cells treated with
2.5, 5, 10, or 20μM α-TEA for two days exhibited dose
dependent apoptosis of 16, 34, 72, and 98 % apoptotic
cells; whereas, A2780/CP70R cells treated with two-fold
higher levels of α-TEA (namely, 5, 10, 20, or 40μM) for
two days exhibited dose dependent apoptosis of 5, 34, 75,
and 97 % apoptotic cells (Figure 1(b)). EC50 values for 2-
day α-TEA treatments of A2780S and A2780/CP70R cells
were 5.6 and 13μM, respectively. Vehicle control treated
cells of either type exhibited a low background level of
apoptosis of approximately 4%. Since treatment of A2780
and A2780/CP70R with 20 and 40μM α-TEA, respectively,
induced optimal amounts of apoptosis, these two diﬀerent
concentrations were used for all the following mechanistic
studies.
3.2. α-TEA Downregulates Two Prosurvival (Antiapoptotic)
Factors, FLIP and Survivin in Both Cell Types and Overex-
pression of Either FLIP or Survivin Partially Rescues A2780S
and A2780/CP70R Cells from α-TEA-Induced Apoptosis.
Treatment of both cell lines with α-TEA decreased protein
levels of FLIP-L, FLIP-S and survivin in a time-dependent
manner (Figure 2(a)). To assess the importance of FLIP and
survivin to α-TEA-induced apoptosis, cells were transiently
transfected with wild-type, his-tagged FLIP-L, myc-tagged
survivin or empty vector (pcDNA3), and treated with
either vehicle control or α-TEA for 24 hours. Percentage of
apoptotic cells were determined (Figure 2(b)) and level of
ectopically expressed proteins were measured (Figure 2(c)).
Overexpression of either wild-type FLIP-L or wild-type
survivin in both cell lines signiﬁcantly suppressed α-TEA-
induced apoptosis, compared to empty vector control (P<
.001; Figure 2(b)), demonstrating that ectopic expression
of FLIP-L or survivin rescues cells from α-TEA-induced
apoptosis.Westernblotanalysesconﬁrmedthattransfections
yielded high levels of the ectopically expressed proteins
(Figure 2(c)). Please note, the Western blot depicted in
Figure 2(c) is from a short exposure time that is inadequate
for visualizing endogenous wildtype survivin expression.
These results demonstrate that α-TEA downregulation of
FLIP-L and survivin is required, at least in part, for
maximum induction of apoptosis.
3.3. α-TEA Decreased Levels of Phosphorylated (Active) Akt.
Phosphorylation of Akt at Ser 473 is required for its full
activation [41]. α-TEA decreased the levels of phospho-Akt
(Ser 473) while having no major eﬀect on levels of total
Akt protein expression in both ovarian cancer cell types
in a time-dependent manner (Figure 3(a)). To verify that
the decrease in phosphorylation status of Akt is correlated
with decreased kinase activity, the phosphorylation status of
GSK3β, a substrate of Akt, was assessed following α-TEAJournal of Oncology 7
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Figure 4: α-TEA downregulates ErbB1, -2, or -3 receptors in A2780S and A2780/CP70R cells. A2780S and A2780/CP70R cells were treated
with 20μMa n d4 0μMo fα-TEA, respectively, for 3, 6, 9, and 12 hours or vehicle control for 12 hours. Cell lysates from treatment groups
were analyzed by immunoblotting for ErbB1, ErbB2, ErbB3 and ErbB4 protein levels. GAPDH levels were determined to verify lane loads
for densitometric analyses with vehicle control given a value of 100. Data are representative of two or more experiments.
treatments. Reduced phosphorylation status of pGSK3β (Ser
9) was detected with little to no corresponding decreases in
protein levels, indicating that α-TEA treatments inhibited
Akt activity (Figure 3(a)).
3.4. Overexpression of Constitutively Active Akt Blocks α-TEA’s
Ability to Reduce FLIP and Survivin Levels. Studies were
conducted to determine if α-TEA downregulation of FLIP
and survivin is mediated by Akt. A constitutively active form
of Akt2 (HA-Myr-AKT2) was overexpressed in both cell
types. Cells transfected with the pcDNA3 vector alone served
as control. Data show that cells transfected with the consti-
tutively active form of Akt exhibited inhibition of α-TEA’s
ability to reduce FLIP and survivin expression (Figure 3(b)).
These data suggest that Akt is an upstream mediator for both
FLIP and survivin and α-TEA downregulation of FLIP and
survivin is mediated via suppression of Akt.
3.5. Inhibition of Akt Using PI3K Inhibitors Enhances α-TEA’s
Ability to Induce Apoptosis and Reduce FLIP and Survivin
Levels. To further investigate the function of active Akt in
the regulation of FLIP and survivin, we used PI3K inhibitors
LY294002 [28] and wortmannin [29] to determine whether
reduced Akt activity eﬀects α-TEA-induced apoptosis and
FLIP and survivin protein expression. Data show that both
LY294002 and wortmannin eﬀectively inhibited the levels of
phosphorylated Akt and GSK3β in both cell lines without
markedly changing total protein levels (Figure 3(c),ﬁ r s t
to fourth panels). Likewise, FLIP and survivin expression
levels were decreased by treatment with either PI3K inhibitor
or α-TEA singly, and further decreased by co-treatments
(Figure 3(c), ﬁfth and sixth panels). Cleavage of caspases-8,
-9, and -3 were enhanced by combination treatments. Like-
wise, PARP proteolytic cleavage as a measure of apoptosis
showed that LY294002 and wortmannin augmented the
apoptotic response induced by α-TEA (Figure 3(c),l a s t4
panels).
3.6. α-TEA Downregulates ErbB Protein Levels in Both
Cell Lines. ErbB family members play important roles in
regulating epithelial cell proliferation and survival via their
downstream mediators, including PI3K/Akt [7]. Therefore,
we investigated whether α-TEA suppresses Akt/FLIP and
survivin pathways via targeting ErbB family members in
A2780S and A2780/CP70R cells. Western immunoblot data
(Figure 4) show that A2780S cells expressed undetectable
ErbB1 and lower levels of ErbB2 and ErbB3 in comparison
with A2780/CP70R cells. α-TEA at 20 or 40μM for 3, 6,
9, or 12 hours in A2780S and A2780/CP70R, respectively,
decreased ErbB1 (A2780/CP70R), and ErbB2 and ErbB3
in both cell lines (Figure 4). GAPDH levels were used to
normalize densitometric values for any variation in lane
loads.
3.7. Investigation of Causal Roles of ErbB2 and ErbB3 in
Akt Signaling in α-TEA-Induced Apoptosis. In this study,
we tested if α-TEA down regulation of ErbB2 or ErbB3
contributes to α-TEA-induced suppression of pAkt and α-
TEA-mediated apoptosis. First, we examined the eﬀects of
functional knockdown of ErbB2 or ErbB3 using siRNA.
Data show that ErbB2 and ErbB3 targeted siRNAs produced
reductions in levels of pAkt in comparison to nonsilencing
siRNA treated controls (Figure 5(a)). As predicted, knock-
down of ErbB2 and ErbB3 enhanced α-TEA suppression of
pAkt and increased α-TEA-mediated apoptosis as measured
by PARP-cleavage (Figure 5(a)).
As shown in Figure 5(b), ErbB2 and ErbB3 were suc-
cessfully over expressed and α-TEA’s ability to reduce pAkt
levels and induce apoptosis were diminished but not totally8 Journal of Oncology
siRNA NS ErbB2 ErbB3 NS ErbB2 ErbB3
α-TEA (20μM) Veh α-TEA (40μM)
A2780S A2780/CP70R
Veh
NS NS ErbB2 ErbB3 ErbB2 ErbB3
ErbB2
ErbB3
p-AKT
(Ser 473)
AKT
Pro-PARP
c-PARP
GAPDH
100 22 99 18 2 15
100 98 29 20 19 5
100 40 21 31 0 0
100 59 97 42 4 39
100 95 50 41 38 6
100 9 8 33 0 0
(a)
Vector Co ErbB3 ErbB2 Co ErbB3 ErbB2
α-TEA (20μM) Veh α-TEA (40μM)
A2780S A2780/CP70R
Veh
Co Co ErbB3 ErbB2 ErbB3 ErbB2
ErbB2
ErbB3
p-AKT
(Ser 473)
AKT
Pro-PARP
c-PARP
GAPDH
100 100 180 5 8 144
100 320 319 30 103 110
100 445 103 23 300 30
100 93 139 4 7 129
100 166 205 10 25 85
100 345 90 8 268 10
(b)
Figure5:DownregulationofErbB2or-3usingsiRNAssensitizeA2780SandA2780/CP70Rcellstoα-TEA-inducedapoptosisandinhibitAkt
phosphorylation; whereas overexpression of ErbB2 or -3 blocks α-TEA-induced apoptosis and enhances phosphorylation of Akt. (a) Cells
weretransfectedwith20μMofsequence-speciﬁcsyntheticsiRNAsagainstErbB2or-3.Nonsilencing(NC)siRNA-transfectedcellswereused
as control. Cells were treated with either vehicle or α-TEA for 9 hours and then lysed. 50μg of total lysate protein was used for detection of
ErbB2, ErbB3, pAkt (Ser 473), total Akt, and PARP by Western blot. Data are depicted as the mean ± SD for three independent experiments.
(b) Cells were transiently transfected with empty vector control (pcDNA3), ErbB2 or ErbB3 plasmids. After 24 hours of transfection, cells
weretreatedwithorwithoutα-TEA for 9 hours, and whole cell extracts examined by immunoblotting. Numbers cited under lanes represent
densitometric analyses for comparative purposes. Data are representative of three independent experiments.
eliminated, suggesting that α-TEA might still be an eﬀective
anticancer agent even in cases of highly elevated ErbB
mediated survival.
Collectively, these results show that ErbB2 and ErbB3
control basal, constitutively active levels of pAkt and down
regulation of ErbB2 and ErbB3 contributes to α-TEA-
induced suppression of pAkt and induction of apoptosis
in both A2780S and A2780/CP70R human ovarian cancer
cells. Conversely, ectopic over expression of ErbB2 or ErbB3
limited α-TEA’s ability to induce apoptosis.
4. Discussion
Data in this paper showed the following: (i) α-TEA is an
eﬀective stand alone anticancer agent for human ovarian
cancer cell lines in that it inhibits both cisplatin-sensitive
and -resistant ovarian cancer cells growth in culture by both
decreasing cell proliferation and inducing apoptosis. (ii) The
downregulation of ErbB2 and ErbB3/Akt/FLIP and survivin
signaling events is necessary for α-TEA-induced apoptosis,
and (iii) ErbB1 is highly expressed in the A2780/CP70R cells
and below levels of detection in the A2780S cells, suggesting
that ErbB1 may play a role in cisplatin resistance. Taken
together with previous data that showed that α-TEA induces
apoptosis via Fas Fas(CD95)/FasL mitochondrial dependent
signaling events [27], we have summarized our current
understanding of α-TEA induced apoptosis in human ovar-
ian cancer cells in Figure 6. α-TEA is an eﬀective anticancer
agent not only because it triggers apoptosis via activation of
membrane death receptor Fas (CD95)-mediated proapop-
totic signaling but also because it downregulates ErbB family
members and their downstream antiapoptotic eﬀectors.Journal of Oncology 9
Pro-survival pathway Pro-apoptotic pathway α-TEA
ErbB 1, 2, 3 Fas
PI3K
FLIP Caspase-8
AKT
tBid
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Figure 6: Schematic of signaling pathways involved in α-TEA-induced apoptosis in human ovarian cancer cell lines. Based on previously
reported data [27] and data reported here, we propose both blockage of prosurvival and activation of proapoptotic signaling pathways are
involved in α-TEA-induced apoptosis of human ovarian cancer cell lines. α-TEA triggers activation of the proapoptotic Fas (CD95) pathway,
leading to a caspase-8- and mitochondria/caspase-9-dependent proapoptotic cascade [27]. Additionally, α-TEA downregulates ErbB1 (in
the A2780/CP70R cells) and ErbB2 and ErbB3 in both A2780 and A2780/CP70R cell lines, leading to suppression of PI3K/Akt signaling
and expression of the downstream antiapoptotic factors FLIP and survivin, which potentiates the α-TEA-induced proapoptotic cascade via
enhancing the activation of caspase-8 and caspase-9/3, respectively, [15–17].
Vitamin E analogs have not been extensively stud-
ied in ovarian cancer. Previously, we reported that α-
TEA in combination with cisplatin signiﬁcantly reduced
A2780/CP70R ovarian cancer tumor burden and lung
metastasis in comparison to single treatments [22], and
that the apoptotic properties of α-TEA in human ovarian
cancer cells was mediated, at least in part, via Fas (CD95)
mitochondrial-dependent apoptotic signaling pathway [27].
Studies by Shanker et al. [42] showed that the succinate
analog of RRR-α-tocopherol, vitamin E succinate, in cell
culture inhibited the growth of MDAH2774 human ovarian
tumor cells via extrinsic and intrinsic apoptotic pathways.
In a study that compared the eﬃcacy of α-TEA versus
vitamin E succinate, we showed α-TEA was a more eﬀective
anticancer agent because esterase activity in ovarian cancer
cells clipped oﬀ the succinic moiety of vitamin E succinate,
yielding RRR-α-tocopherol which does induce apoptosis
[26]. The ability of α-TEA to induce apoptosis in human
ovarian cancer cell lines is not restricted to A2780 and
A2780/CP70R cells but has been shown in a number of
human ovarian cancer cell lines including 2008, 2008-
C13, Hey, OVCA-429, OVCA-433, OVCA-432 and SK-OV-3
[26].
The ability of α-TEA to induce apoptosis in both
A2780S and A2780/CP70 ovarian cancer cells requires
both downregulation of ErbB-mediated prosurvival fac-
tors (ErbB/Akt/FLIP and survivin) and activation of Fas-
mediated mitochondrial dependent apoptosis, two comple-
mentary and necessary events.
T h em e m b r a n ea s s o c i a t e de p i d e r m a lg r o w t hf a c t o r
receptor family (ErbB) members possess protein tyrosine
kinase activity, are involved in cell survival and proliferation
and are ampliﬁed in many cancers [43]. Ampliﬁcation
of ErbB2 protein is found in approximately one third of
ovarian cancers and is an indicator of poor prognosis
in advanced disease [44]. ErbB2 initiates several signaling
networksinvolvedinavarietyofcellularprocesses,including
PI3K/Akt [44]. Akt is constitutively active in ovarian cancers,
and contributes to tumor cell survival by promoting the
expression of survivin [37, 45].
Although direct measurements of Akt activity were not
performed, decreased phosphorylation status of a down-
stream target of Akt, namely GSK3β was observed following
α-TEA treatment, indicating that α-TEA-is downregulating
Akt activity. Akt was shown to play a role in α-TEA induced
apoptosis since expression of constitutively active Akt210 Journal of Oncology
partially prevented α-TEA-induced apoptosis, and chemical
inhibition of the PI3K/Akt pathway augmented α-TEA-
induced apoptosis as measured by caspase-8 and casapse-9
activation, as well as PARP cleavage. Furthermore, the ability
ofα-TEA,viadownregulationofAkt,toreduceFLIPandsur-
vivin provide further evidence that ErbB/Akt/FLIP/survivin
signaling events help maintain ovarian cancers.
Based on studies reported here that suppression of Akt,
FLIP or survivin in the absence of α-TEA did not induce
apoptosis, suggests that these ovarian cancer cells are not
“addicted” to PI3K/Akt/cFLIP/survivin for survival. Rather
data show that suppression of ErbB/Akt/FLIP/survivin anti-
apoptotic pathway cooperates with α-TEA-induced death
receptor-mediated mitochondrial-dependent apoptotic cas-
cade to sensitize the cells to cell death signals. As depicted
in Figure 6, inhibition of FLIP and survivin are predicted
to impact the death signaling pathway at both initiation
(caspase 8) and execution (caspases 9 and 3) phases [15,
16]. Both FLIP and survivin have been implicated in
contributingtocisplatinresistanceinovariancancer[27,46].
Therefore, downregulation of ErbB/Akt/FLIP and survivin
prosurvival pathway by α-TEA not only enhances α-TEA-
induced apoptosis but may also sensitize ovarian cancer cells
to other proapoptotic agents.
5. Conclusion
Aberrant activation of ErbB receptors and downstream
PI3K/Akt signaling contributes to the development of many
cancers, including ovarian cancer. This report demonstrates
that α-TEA is a potent inducer of apoptosis in both cisplatin-
sensitive and -resistant human ovarian cancer cell lines in
culture.α-TEA’sabilitytoinitiateapoptosisisenhancedbyits
ability to downregulate ErbBs and subsequent downstream
prosurvival mediators, Akt, and Akt mediated FLIP and
survivin, yielding a dual-acting agent. A more complete
understanding of α-TEA’s multiple actions, not only adds to
our basic understanding of dysregulated signaling in cancer
pathophysiologybuthopefullywillaidinselectingtheproper
application of α-TEA in the clinic.
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